© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
UNIVERSITY OF TEXAS HEALTH CENTER AT TYLER
2303 SE MILITARY DR
November 15, 2016
Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab-which conceivably could ultimately cure CLL.
June 15, 2015
October 10, 2014
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.